Methionine PET/CT Studies In Patients With Cancer
The study focuses on the following objectives:
- To estimate the success rate of Methionine (MET) for visualizing tumors at the time of
diagnosis. The study hypothesizes that at least 70% of newly diagnosed tumors within
each group will be studied and will be successfully visualized.
- To compare uptake of MET in tumors with tumor grade in patients with newly diagnosed or
relapsed, and/or persistent disease. Hypothesis: high grade tumors will concentrate
higher amounts of MET than lower grade tumors measured both qualitatively and
- To examine the bio-distribution of MET in organs that do not contain tumor, in
particular the lungs, heart, mediastinum, liver, spleen, pancreas, muscle, brain, and
- To compare the findings on MET PET scans with those of standard imaging modalities,
principally MRI (magnetic resonance imaging) and FDG (fluorodeoxyglucose) PET CT
(computed tomography) at diagnosis, or at study enrollment for patients with relapsed
and or persistent disease, and for all patients over time.
- To compare the extent of abnormality on MRI with that of MET.
- To determine the presence or absence of elevated MET uptake beyond those of MRI defined
- To explore the relationship between MET uptake and prognosis.
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic
Success rate of methionine (MET) for visualizing tumors
To estimate the success rate of methionine (MET) for visualizing tumors at the time of diagnosis. We hypothesize that at least 70% of tumors within each group studied will be successfully visualized.
Barry L Shulkin, MD
St. Jude Children's Research Hospital
United States: Institutional Review Board
|St. Jude Children's Research Hospital||Memphis, Tennessee 38105-2794|